

# Neuroendocrine Tumors (NETs) - Epidemiology Forecast to 2032

<https://marketpublishers.com/r/NB1365A5A19EN.html>

Date: January 2022

Pages: 60

Price: US\$ 3,950.00 (Single User License)

ID: NB1365A5A19EN

## Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Neuroendocrine Tumors (NETs) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Neuroendocrine Tumors (NETs) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

### Geographies Covered

The United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2019-2032

### Neuroendocrine Tumors (NETs) Understanding

The DelveInsight Neuroendocrine Tumors (NETs) epidemiology report gives a thorough understanding of the Neuroendocrine Tumors (NETs) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Neuroendocrine Tumors (NETs) in the US, Europe, and Japan. The report covers the detailed information of the Neuroendocrine Tumors (NETs) epidemiology scenario in seven major countries (US,

EU5, and Japan).

## Neuroendocrine Tumors (NETs) Epidemiology Perspective by DelveInsight

The Neuroendocrine Tumors (NETs) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Neuroendocrine Tumors (NETs) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Neuroendocrine Tumors (NETs) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

## Neuroendocrine Tumors (NETs) Detailed Epidemiology Segmentation

The Neuroendocrine Tumors (NETs) epidemiology covered in the report provides historical as well as forecasted Neuroendocrine Tumors (NETs) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Neuroendocrine Tumors (NETs) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

## Scope of the Report

The Neuroendocrine Tumors (NETs) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

The Neuroendocrine Tumors (NETs) Epidemiology Report and Model provide an overview of the global trends of Neuroendocrine Tumors (NETs) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)

The report provides insight into the historical and forecasted patient pool of Neuroendocrine Tumors (NETs) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan

The report helps recognize the growth opportunities in the 7MM for the patient population

The report assesses the disease risk and burden and highlights the unmet needs of Neuroendocrine Tumors (NETs)

The report provides the segmentation of the Neuroendocrine Tumors (NETs) epidemiology

## Report Highlights

11-year Forecast of Neuroendocrine Tumors (NETs) epidemiology

7MM Coverage

Prevalent and Diagnosed Cases of Neuroendocrine Tumors (NETs)

Cases of Neuroendocrine Tumors (NETs) by Mutation Types

Neuroendocrine Tumors (NETs) Cases associated with Clinical Manifestations

## KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

## Key Questions Answered

What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Neuroendocrine Tumors (NETs)?

What are the key findings pertaining to the Neuroendocrine Tumors (NETs) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?

What would be the total number of patients of Neuroendocrine Tumors (NETs) across the 7MM during the forecast period (2019-2032)?

Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?

At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

What is the disease risk, burden and unmet needs of Neuroendocrine Tumors (NETs)?

What are the currently available treatments of Neuroendocrine Tumors (NETs)?

## Reasons to buy

The Neuroendocrine Tumors (NETs) Epidemiology report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the global Neuroendocrine Tumors (NETs) market

Quantify patient populations in the global Neuroendocrine Tumors (NETs) market to improve product design, pricing, and launch plans

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Neuroendocrine Tumors (NETs) therapeutics in each of the markets covered

Understand the magnitude of Neuroendocrine Tumors (NETs) population by its epidemiology

The Neuroendocrine Tumors (NETs) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

## Key Assessments

Patient Segmentation

Disease Risk & Burden

Risk of disease by the segmentation

Factors driving growth in a specific patient population

## Contents

### 1. KEY INSIGHTS

### 2. EXECUTIVE SUMMARY OF NEUROENDOCRINE TUMORS (NETS)

### 3. NEUROENDOCRINE TUMORS (NETS): DISEASE BACKGROUND AND OVERVIEW

#### 3.1. Introduction

#### 3.2. Sign and Symptoms

#### 3.3. Pathophysiology

#### 3.4. Risk Factors

#### 3.5. Diagnosis

### 4. PATIENT JOURNEY

### 5. EPIDEMIOLOGY AND PATIENT POPULATION

#### 5.1. Epidemiology Key Findings

#### 5.2. Assumptions and Rationale: 7MM

#### 5.3. Epidemiology Scenario: 7MM

##### 5.3.1. Neuroendocrine Tumors (NETs) Epidemiology Scenario in the 7MM (2019-2032)

#### 5.4. United States Epidemiology

##### 5.4.1. Neuroendocrine Tumors (NETs) Epidemiology Scenario in the United States (2019- 2032)

#### 5.5. EU-5 Country-wise Epidemiology

##### 5.5.1. Germany Epidemiology

###### 5.5.1.1. Neuroendocrine Tumors (NETs) Epidemiology Scenario in Germany (2019-2032)

##### 5.5.2. France Epidemiology

###### 5.5.2.1. Neuroendocrine Tumors (NETs) Epidemiology Scenario in France (2019-2032)

##### 5.5.3. Italy Epidemiology

###### 5.5.3.1. Neuroendocrine Tumors (NETs) Epidemiology Scenario in Italy (2019- 2032)

##### 5.5.4. Spain Epidemiology

###### 5.5.4.1. Neuroendocrine Tumors (NETs) Epidemiology Scenario in Spain (2019-2032)

#### 5.5.5. United Kingdom Epidemiology

5.5.5.1. Neuroendocrine Tumors (NETs) Epidemiology Scenario in the United Kingdom (2019-2032)

#### 5.6. Japan Epidemiology

5.6.1. Neuroendocrine Tumors (NETs) Epidemiology Scenario in Japan (2019- 2032)

### **6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES**

6.1. Neuroendocrine Tumors (NETs) Treatment and Management

6.2. Neuroendocrine Tumors (NETs) Treatment Algorithm

### **7. KOL VIEWS**

### **8. UNMET NEEDS**

### **9. APPENDIX**

9.1. Bibliography

9.2. Report Methodology

### **10. DELVEINSIGHT CAPABILITIES**

### **11. DISCLAIMER**

### **12. ABOUT DELVEINSIGHT**

\*The table of contents is not exhaustive; will be provided in the final report

## List Of Tables

### LIST OF TABLES

List of Table:

Table 1: Neuroendocrine Tumors (NETs) Epidemiology in 7MM (2019-2032)

Table 2: Neuroendocrine Tumors (NETs) Diagnosed and Treatable Cases in 7MM (2019-2032)

Table 3: Neuroendocrine Tumors (NETs) Epidemiology in the United States (2019-2032)

Table 4: Neuroendocrine Tumors (NETs) Diagnosed and Treatable Cases in the United States (2019-2032)

Table 5: Neuroendocrine Tumors (NETs) Epidemiology in Germany (2019-2032)

Table 6: Neuroendocrine Tumors (NETs) Diagnosed and Treatable Cases in Germany (2019-2032)

Table 7: Neuroendocrine Tumors (NETs) Epidemiology in France (2019-2032)

Table 8: Neuroendocrine Tumors (NETs) Diagnosed and Treatable Cases in France (2019-2032)

Table 9: Neuroendocrine Tumors (NETs) Epidemiology in Italy (2019-2032)

Table 10: Neuroendocrine Tumors (NETs) Diagnosed and Treatable Cases in Italy (2019-2032)

Table 11: Neuroendocrine Tumors (NETs) Epidemiology in Spain (2019-2032)

Table 12: Neuroendocrine Tumors (NETs) Diagnosed and Treatable Cases in Spain (2019-2032)

Table 13: Neuroendocrine Tumors (NETs) Epidemiology in the United Kingdom (2019-2032)

Table 14: Neuroendocrine Tumors (NETs) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)

Table 15: Neuroendocrine Tumors (NETs) Epidemiology in Japan (2019-2032)

Table 16: Neuroendocrine Tumors (NETs) Diagnosed and Treatable Cases in Japan (2019-2032)



## List Of Figures

### LIST OF FIGURES

#### List of Figures

Figure 1 Neuroendocrine Tumors (NETs) Epidemiology in 7MM (2019-2032)

Figure 2 Neuroendocrine Tumors (NETs) Diagnosed and Treatable Cases in 7MM (2019-2032)

Figure 3 Neuroendocrine Tumors (NETs) Epidemiology in the United States (2019-2032)

Figure 4 Neuroendocrine Tumors (NETs) Diagnosed and Treatable Cases in the United States (2019-2032)

Figure 5 Neuroendocrine Tumors (NETs) Epidemiology in Germany (2019-2032)

Figure 6 Neuroendocrine Tumors (NETs) Diagnosed and Treatable Cases in Germany (2019-2032)

Figure 7 Neuroendocrine Tumors (NETs) Epidemiology in France (2019-2032)

Figure 8 Neuroendocrine Tumors (NETs) Diagnosed and Treatable Cases in France (2019-2032)

Figure 9 Neuroendocrine Tumors (NETs) Epidemiology in Italy (2019-2032)

Figure 10 Neuroendocrine Tumors (NETs) Diagnosed and Treatable Cases in Italy (2019-2032)

Figure 11 Neuroendocrine Tumors (NETs) Epidemiology in Spain (2019-2032)

Figure 12 Neuroendocrine Tumors (NETs) Diagnosed and Treatable Cases in Spain (2019-2032)

Figure 13 Neuroendocrine Tumors (NETs) Epidemiology in the United Kingdom (2019-2032)

Figure 14 Neuroendocrine Tumors (NETs) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)

Figure 15 Neuroendocrine Tumors (NETs) Epidemiology in Japan (2019-2032)

Figure 16 Neuroendocrine Tumors (NETs) Diagnosed and Treatable Cases in Japan (2019-2032)

\*The table of contents is not exhaustive; will be provided in the final report

## I would like to order

Product name: Neuroendocrine Tumors (NETs) - Epidemiology Forecast to 2032

Product link: <https://marketpublishers.com/r/NB1365A5A19EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NB1365A5A19EN.html>